Novo Nordisk (NVO) reportedly plans to phase out production of its human insulin pens while it ramps up production of other ...
Novo Nordisk said Thursday that it plans to eventually halt all of its human insulin pen production globally, ...
Novo Nordisk is ceasing production of human insulin pens, focusing on newer obesity and diabetes injections. This shift has ...
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...
Traditionally, scientists believed that obesity led to type 2 diabetes by impairing insulin signaling within liver and fat ...
Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...
The international medical charity Doctors Without Borders has called on leading pharmaceutical corporations and "all insulin ...
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...
Ahead of World Diabetes Day, Doctors Without Borders (MSF) called on pharmaceutical corporations Eli Lilly, Novo Nordisk, Sanofi, and all insulin manufacturers to take urgent action to increase access ...
The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®). In China's 2024 National Insulin-Specific Centralized ...
Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback